Abstract 1019P
Background
The efficacy of immune checkpoint inhibitors (ICIs) in SMARCA4 mutant non-small cell lung cancer (NSCLC) is limited. CD8+ T cell exhaustion plays an important role in damaging anti-tumor immunity, but the molecular mechanisms remain unclear.
Methods
We compared the survival difference between patients with SMARCA4 mutation and wild type. The RNA sequencing of CD8+T cells sorted from tumor tissues was performed. The SMARCA4 mutant-H1299 cells were implanted into the left flank of the NSG mice. 2×107 human PBMCs were separated and injected intravenously into NSG mice to establish humanized NSG mouse models. Anti-PD-1 of Bispecific PD1-IL2 antibody were given intraperitoneally. The frequencies and phenotypes of CD8+T cells in mouse spleens and blood were detected by flow cytometry while those in tumor tissues were determined by multiplex immunofluorescence (mIF). The mIF staining was performed to validate differences of CD8+ T cells exhaustion phenotype between SMARCA4 mutant and wild-type patient tissues.
Results
Treatment with ICIs could not improve outcomes in patients with SMARCA4 mutations (P = 0.754). The analysis of RNA sequencing showed that the production of interleukin-2 (IL-2) was significantly reduced in CD8+T cells of SMARCA4 mutant Lewis lung carcinoma (P < 0.001). The analysis of mIF revealed that the infiltration of PD1+CD8+, LAG3+CD8+, TIM3+CD8+ T cells increased in SMARCA4 mutant tumor tissues. We found that a high level of IL-2 leads to the persistent activation of STAT5 in CD8+ T cells. Bispecific PD1-IL2 antibody enhanced anti-tumor immunity and suppressed tumor progression by reversing CD8+T cells exhaustion.
Conclusions
The PD1-IL2 bispecific antibody could reverse CD8+T cell exhaustion to enhance anti-tumor immunity in SMARCA4 mutant NSCLC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
H. Wang.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1046P - Genetic alteration profile and T Cell receptor repertoire in severe immune-related adverse events during checkpoint immunotherapy
Presenter: Yi Hu
Session: Poster session 03
Resources:
Abstract
1047P - Tocilizumab is an effective secondary prophylaxis during immune checkpoint inhibitor rechallenge following arthritis
Presenter: Michel Obeid
Session: Poster session 03
1048P - Cardiovascular toxicities in cancer patients treated with immune checkpoint inhibitors: Evidence from a Belgian real-world multicenter study
Presenter: Danielle Delombaerde
Session: Poster session 03
1049P - Cytokine release syndrome in patients treated with bispecific T cell engagers and bispecific monoclonal antibodies at The Christie: A retrospective study
Presenter: Mariam Shalaby
Session: Poster session 03
1050P - Independent of calendric age, T cells are phenotypically less senescent in successfully ICI-treated cancer patients that developed irAE
Presenter: Sarah Roffeis
Session: Poster session 03
1051P - Impact of TLS status on outcomes in patients with high TMB or MSI-high status treated with immune checkpoint inhibitors
Presenter: Antoine Italiano
Session: Poster session 03
Resources:
Abstract
1052P - Pan-cancer, multi-omic analysis of 'hot' and 'cold' tumors reveals immunotherapy relevant signatures
Presenter: Elisabetta Nale
Session: Poster session 03
1053P - The prognostic value of systemic inflammatory markers among patients receiving immune checkpoint inhibitors (ICIs): A population-based study
Presenter: Abdulrahman Alghabban
Session: Poster session 03
1054P - CRUCIAL: Analysis of the incidence of second primary cancers in the Spanish thoracic tumor registry according to treatment
Presenter: Mariano Provencio Pulla
Session: Poster session 03
1055P - Analysis of correlation between quality of life (QoL) results and survival outcomes in phase III clinical trials testing immunotherapy in metastatic cancers
Presenter: Annarita Avanzo
Session: Poster session 03